Isis gets $3.5M as antisense drug trial proceeds

05/12/2013 | Genetic Engineering & Biotechnology News

Biogen Idec paid Isis Pharmaceuticals a $3.5 million milestone fee after the dosing of the first infant with spinal muscular atrophy in a midstage trial of the antisense drug ISIS-SMN. The open-label study, which will involve eight infants with the condition, will be carried out in the U.S. and Canada.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN